Table 2 Availability of reproductive health commodity and supply by observation, Ethiopia, 2022
Variable | PH (n = 37) n (%) | HC (n = 39) n (%) | HP (n = 35) n (%) |
|---|---|---|---|
Combined oral contraceptive pills | 32 (86.5) | 29 (74.4) | 19 (54.3) |
Progestin-only contraceptive pills | 27 (73.0) | 28 (71.8) | 18 (51.4) |
Depo-Provera | 33 (89.2) | 33 (84.6) | 28 (80.0) |
Male condoms | 33 (89.2) | 31 (79.5) | 25 (71.4) |
Female condoms | 3 (8.1) | 8 (20.5) | 3 (8.6) |
Levonorgestrel implant (Jadelle®) | 16 (43.2) | 8 (20.5) | 6 (17.1) |
Etonogestrel implant (Single Rod Implanon) | 32 (86.5) | 33 (84.6) | 23 (65.7) |
Ulipristal acetate tablet 30 mg (emergency contraceptive) | 14 (37.8) | 9 (23.1) | 6 (17.1) |
Mifepristone tablet 10–25 mg (emergency contraceptive) | 23 (62.2) | 16 (41.0) | 5 (14.3) |
Intrauterine contraceptive device (IUCD) | 34 (91.9) | 32 (82.1) | 7 (20.0) |
National FP guidelines | 24 (61.5) | 26 (61.9) | 10 (25.6) |
FP check-lists and/or job-aids | 32 (82.1) | 33 (78.6) | 24 (61.5) |